[HTML][HTML] BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

A Alu, H Lei, X Han, Y Wei, X Wei - Journal of Hematology & Oncology, 2022 - Springer
Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

[HTML][HTML] MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

SE Ahmadi, S Rahimi, B Zarandi, R Chegeni… - Journal of hematology & …, 2021 - Springer
MYC oncogene is a transcription factor with a wide array of functions affecting cellular
activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to …

[HTML][HTML] Drug resistance in non-Hodgkin lymphomas

P Klener, M Klanova - International journal of molecular sciences, 2020 - mdpi.com
Non-Hodgkin lymphomas (NHL) are lymphoid tumors that arise by a complex process of
malignant transformation of mature lymphocytes during various stages of differentiation. The …

[HTML][HTML] Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)

G Shabir, A Saeed, W Zahid, F Naseer, Z Riaz… - Pharmaceuticals, 2023 - mdpi.com
Fluorine is characterized by high electronegativity and small atomic size, which provide this
molecule with the unique property of augmenting the potency, selectivity, metabolic stability …

[HTML][HTML] T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma

ZZ Yang, HJ Kim, H Wu, X Tang, Y Yu, J Krull… - Blood cancer …, 2023 - nature.com
T-lymphocytes are prevalent in the tumor microenvironment of follicular lymphoma (FL).
However, the phenotype of T-cells may vary, and the prevalence of certain T-cell subsets …

B-cell lymphoma 6 (BCL6): from master regulator of humoral immunity to oncogenic driver in pediatric cancers

T McLachlan, WC Matthews, ER Jackson… - Molecular Cancer …, 2022 - AACR
Abstract B-cell lymphoma 6 (BCL6) is a protooncogene in adult and pediatric cancers, first
identified in diffuse large B-cell lymphoma (DLBCL) where it acts as a repressor of the tumor …

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

SS Neelapu, JC Chavez, AR Sehgal, N Epperla… - Blood, 2024 - ashpublications.org
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor
(CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL) …

[HTML][HTML] Immune-checkpoint inhibitors in B-cell lymphoma

M Armengol, JC Santos, M Fernández-Serrano… - Cancers, 2021 - mdpi.com
Simple Summary Immune-based treatment strategies, which include immune checkpoint
inhibition, have recently become a new frontier for the treatment of B-cell-derived lymphoma …

PI3k inhibitors in NHL and CLL: an unfulfilled promise

N Bou Zeid, V Yazbeck - Blood and Lymphatic Cancer: Targets and …, 2023 - Taylor & Francis
Abstract Phosphatidylinositol 3-kinases (PI3Ks) are a family of intracellular signal transducer
enzymes that can attach a phosphate group to the 3'-hydroxyl of the inositol moiety of …

[HTML][HTML] The roles of IL-22 and its receptor in the regulation of inflammatory responses in the brain

D Lee, H Jo, C Go, Y Jang, N Chu, S Bae… - International Journal of …, 2022 - mdpi.com
Interleukin (IL)-22 is a potent mediator of inflammatory responses. The IL-22 receptor
consists of the IL-22Rα and IL-10Rβ subunits. Previous studies have shown that IL-22Rα …